Biodexa Sets July 29 Vote on 1-for-10,000 Reverse Split and £25M Share Authorization
BDRX is trading near its 52-week low of $2.45 (5.7% above the low).
Summary
Biodexa Pharmaceuticals has called a July 29 shareholder meeting to vote on a 1-for-10,000 reverse stock split and a £25 million share authorization, just days after a similar reverse split proposal was rejected.
Key Events · Corporate Governance and Compliance · BDRX
-
New Reverse Split Vote Set for July 29
Shareholders will vote on a 1-for-10,000 reverse stock split, consolidating every 10,000 existing ordinary shares into one new ordinary share, after a previous reverse split proposal was rejected on June 30.
-
£25 Million Share Authorization Sought
Resolution 2 seeks authority to allot shares up to an aggregate nominal value of £25,000,000, providing flexibility for acquisitions and financings through 2029.
-
Pre-emption Rights Waiver Proposed
Resolution 3 would allow the board to issue shares for cash without first offering them to existing shareholders, up to the same £25 million nominal limit.
-
Share Capital Reorganization Details
The reorganization would reduce outstanding ordinary shares from ~452 billion to ~45.2 million New Ordinary Shares, with the ADS ratio changing from 500,000:1 to 50:1, leaving ADS count unchanged.
Analysis · BDRX · Life Sciences
Just nine days after shareholders rejected a 1-for-10,000 reverse split, Biodexa is making another attempt to shrink its bloated share count. The new proposal couples the reverse split with a sweeping £25 million share authorization and a waiver of pre-emption rights — effectively handing the board a blank check to issue shares for acquisitions and financings through 2029. For a company with a market cap barely above $1 million, that authority is enormous and could fund transformative deals or deeply dilutive survival raises. The vote is set for July 29; if it fails again, the company remains stuck with over 452 billion shares outstanding and limited financing flexibility.
How filings like this one have moved
In the 30 days to Aug 22, 2026, 37.5% of the 3496 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BDRX was trading at $2.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2M. The 52-week trading range was $2.45 to $66.50. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.